Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

Table 3 ROC analysis of the dose-volume histogram parameters of the lung and incidence of radiation pneumonitis of grade 2 or more

Dose (Gy)	AUC	Threshold level (%)	Cumulative incidence of G2RP at 6 months		p value
Dose (Gy)	AUC	Threshold level (%)	≥ threshold	< threshold	p value
Lung V50	0.640	5.3	56.8	13.6	0.008
Lung V40	0.686	10.0	57.3	16.7	0.011
Lung V30	0.644	15.7	57.3	26.1	0.048
Lung V20	0.608	23.0	56.4	29.8	0.16
Lung V10	0.566	34.1	52.9	30.0	0.12
Lung V5	0.570	48.2	55.0	30.5	0.07
Mean lung dose	0.640	12.1	54.0	21.1	0.046
Lung Vs5 (ml)	0.533	1364	41.1	37.6	0.62
Initial PTV (ml)	0.679	398	58.3	23.8	0.024

ROC receiver-operating characteristic, G2RP radiation pneumonitis of grade2 or more, Lung Vx percentage of the lung volume exceeding x Gy, Lung Vs5 volume of the lung received less than 5 Gy, PTV planning target volume

ISSN: 1748-717X